Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
PHARMA - DRUGS RISKS AND BENEFITS

Pfizer to offer drugs risk/benefit summary to consumers 

 

BY OUR PHARMA CORRESPONDENT

19th August, 2005: The US drug giant Pfizer will provide consumer-friendly risk/benefit summary for its products, which the company has submitted to the Food and Drug Administration (FDA). As part of its programme to address growing controversy surrounding the promotion of prescription drugs to consumers in the US, Pfizer is making fundamental changes to its direct-to-consumer (DTC) advertising campaigns. 

The proposed changes in three major areas are aimed at improving consumer understanding of the benefits and risks of a treatment, encouraging more dialogue between patients and doctors, and motivating people to overcome potential barriers to better health, as Pfizer release said. Also as part of the changes, the company will inform patients in television and print advertising, and on product websites, that their doctor may recommend alternative treatments. 

The firm will also invest a `meaningful amount' - similar to the figure it spends on a branded ad - in creating more disease awareness campaigns, such as Why Live With Depression? which featured Sopranos star, Lorraine Bracco. 

All DTC activities will be consistent with the Guiding Principles voluntary code from the Pharmaceutical Research and Manufacturers of America (PhRMA) along with a number of other pharma companies, including Bristol-Myers Squibb (BMS), Johnson & Johnson and Wyeth, the release said.

Recently, Pfizer has announced that it would wait at least six months before advertising new prescription drugs to consumers and air ads for its impotence treatment Viagra only during programmes with at least 90 per cent adult viewing, putting an end to such campaigns appearing in breaks in the Super Bowl. 

Researches suggest that DTC advertising can be an effective vehicle for communicating important health information to consumers. However, intense criticism and a raft of complaints from patients and doctors claiming that promotion exaggerates the benefits and downplays the risks of prescription drugs, have forced pharma companies to rethink their approach to the practice. 

BMS has developed its own promotional code of conduct, the Direct-to-Consumer Communications Code, which has been posted on its homepage and is consistent with PhRMA's Guiding Principles. 

Promising to include information about patient assistant programmes in its advertising and developing disease state awareness advertising, BMS says for at least 12 months after the launch of a new drug it will not advertise direct to consumers either on television, radio or in print. Instead, it said, during that time it will invest in educating healthcare professionals about the new drug. 

Wyeth has also given its backing to the PhRMA guidelines, which it believes 'provide a responsible framework for advertising communication'. 

BY OUR PHARMA CORRESPONDENT

Pharma News Headlines

Cancer News

Cardiac News

US FDA News

Pharma industry news

Diseases - Alzheimer's, Parkisonson's and Obesity

Contraception and Abortion News

LATEST UPDATES

Anti fungal terbinafine launched in Europe: Actavis

HIV entry blocking drug data encouraging: Progenics

Allegra generic to be launched in US

Long-acting pain drug data positive: Pain Therapeutics

New kidney cancer drug seeks EU nod

Inhaled insulin may get US FDA clearance

A vaccine against fungus is on way

Enzyme stops progression of HIV in survivors, confirms study

Aclasta found faster-acting in Paget's disease treatment

Beta blocker can start therapy in heart failure: Merck

Halobetasol generic launched in US

Anemia drug darbepoetin's late-stage studies begin: Amgen

Cholesterol generic gets marketing nod in US: Par

Aricept for severe Alzheimer’s disease too: Eisai

Bone regeneration trials begin in US:Mesoblast

New dye to detect early Alzheimer's

Breast forming gene discovered

Thyroid drug to be supplied by IVAX in US

Rituxan, cancer drug can treat rheumatoid arthritis

Yasminelle, low-dose oral contraceptive approved in the Netherlands

Fluarix, anti-flu shot by Glaxo approved

Increlex, drug to treat `abnormally short’ kids approved in US

Anti-HIV drugs prices cut: Gilead

US FDA approves Takeda’s drug combo for type 2 diabetes

Novartis’ drug for breast cancer recurrence to be given priority review in US

US puts off decision on contraceptive pill again

Shire’s ADHD drug Adderall back on list in Canada

WHO calls for emergency action to halt TB in Africa

Some of the Vioxx suits may be settled: Merck

Nasdaq delists Able on bankruptcy filing

Hospira ships ceftriaxone generics to US

Renovis stops sciatica drug studies

Merck sets up generic arm Genpharm in US

Morning after pills still not within easy reach in US

New cancer combo therapy results positive:OXiGENE

Aceon approved for heart disease treatment in US

Cell Therapeutics to seek approval for lung cancer therapy in US and Europe

Anti-depressant Seroxat defended by GSK against new findings

Vioxx verdict: Merck’s defeat to trigger thousands of lawsuits from US, UK

Aspirin stops colon cancer, but may trigger bleeding

New blood test method approved in US

Skin disease drug turns into anti-tumor therapy for cancer

Step-by-Step instructions for dealing with Asthma Attacks

Potential Alzheimer's Disease drugs under investigation

New Molecule may help obese lose weight

Paxil (Paroxetine) may heighten suicide risks, finds study

"Breast cancer chances higher due to fried chips"

Safety alert on Gambro Dasco’s Prisma renal system

Merck responsible for Vioxx death: Jury

Heart disease deaths more among New Yorkers

Pfizer to offer drugs risk/benefit summary to consumers 

Merck lied to public on Vioxx: lawyer tells jurors

Novartis acquires rights of kidney dialysis drug from SeBo

J&J's Concerta approved treatment of ADHD in teenagers in Canada

US FDA stalls Roche’ Accutane use in pregnancy

Novo Nordisk, Eli Lilly remove insulin products from Australia

British drug supply chain safety questioned after another fake Lipitor find

Wyeth starts support programme for Effexor patients

P&G’s Actonel with Calcium approved for osteoporosis

Pozen gets patent on pain management product

Genmab studies new drug for rheumatoid arthritis

Painkillers may increase blood pressure: study

Nektar buys out Aerogen for $32 m

Predix records positive data on anxiety drug

Insmed files against Increlex approval

Hepatitis A vaccine for kids approved in US

Psoriasis drug data positive: Cytochroma

Novo Nordisk’s 24-hour acting insulin Levemir gets US FDA okay

US FDA approves Teva's generic for osteoporosis 

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us